Placid0

Placid0 is a private, clinical-stage biotechnology company focused on developing innovative small molecule therapies for metabolic and inflammatory diseases. The company was founded by Mark Pruzanski, M.D., the former founder and CEO of Intercept Pharmaceuticals, who led the development of the first approved treatment for primary biliary cholangitis in decades. Placid0's lead research program centers on dual agonists of the GPR40 and GPR120 receptors, which are key regulators of insulin secretion and anti-inflammatory pathways. By simultaneously targeting these receptors, the company aims to address the complex pathophysiology of Type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH). Placid0 is currently advancing its lead candidate, PL001, through early clinical trials to evaluate its safety and efficacy in metabolic indications.